Safety of selective serotonin reuptake inhibitors in pregnancy

CNS Drugs

Volumn 23, Issue 6, 2009, Pages 493-509

  Alwan, Sura ^a   Friedman, Jan M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATION; BEHAVIOR DISORDER; BIRTH DEFECT; CARDIOVASCULAR MALFORMATION; CASE CONTROL STUDY; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG UTILIZATION; EYE MALFORMATION; FEEDING DISORDER; FEMALE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HALF LIFE TIME; HIGH RISK PREGNANCY; HUMAN; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; JAUNDICE; LIMB MALFORMATION; LOW BIRTH WEIGHT; MUSCLE RIGIDITY; NAUSEA; NERVOUSNESS; NONHUMAN; POPULATION RESEARCH; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RESTLESSNESS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SHIVERING; SIDE EFFECT; SLEEP DISORDER; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; TREMOR; VOMITING; WITHDRAWAL SYNDROME;

ABNORMALITIES, DRUG-INDUCED; DEPRESSIVE DISORDER; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 66749187822     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923060-00004     Document Type: Review

References (96)

1. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264-9
2. Ryan D, Milis L, Misri N. Depression during pregnancy. Can Fam Physician 2005 Aug; 51: 1087-93
3. Wadhwa PD, Sandman CA, Porto M, et al. The association between prenatal stress and infant birth weight and gesta-tional age at birth: a prospective investigation. Am J Obstet Gynecol 1993; 169: 858-65
4. Chung TK, Lau TK, Yip AS, et al. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001; 63 (5): 830-4
5. Hobel CJ, Goldstein A, Barrett ES. Psychosocial stress and pregnancy outcome. Clin Obstet Gynecol 2008; 51 (2): 333-48
6. Moses-Kolko EL, Roth EK. Antepartum and postpartum depression: healthy mom, healthy baby. J Am Med Wo-mens Assoc 2004; 59 (3): 181-91
7. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-34
8. Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 2188-90
9. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55 Suppl. A: 6-22
10. Morrison JL, Riggs KW, Rurak DW. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev 2005; 17 (6): 641-50
11. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
12. US Food Drug Administration. FDA Public Health Advisory: paroxetine 2005 [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/ paroxetine200512.htm [Accessed 2008 Jan 18]
13. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 221-2
14. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16 (10): 1075-85
15. US Food Drug Administration. FDA Public Health Advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns 2006 [online]. Available from URL: http://www. fda.gov/cder/drug/advisory/SSRI-PPHN200607.htm [Accessed 2008 Jan 18]
16. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8
17. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-5
18. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-10
19. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol 2008; 66 (5): 695-705
20. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy: HMO Research Network Center for Education, Research in Therapeutics. Pharmacoepidemiol Drug Saf 2007; 16 (10): 1086-94
21. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61
22. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17 (6): 701-4
23. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006 Apr; 194 (4): 961-6
24. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A 2007; 79 (4): 301-8
25. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289-96
26. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80 (1): 18-27
27. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects: National Birth Defects Prevention Study. N Engl J Med 2007; 256 (26): 2684-92
28. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356 (26): 2675-83
29. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B 2008; 83: 68-76
30. Ramos E, St-Andre M, Rey E, et al. Duration of anti-depressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344-50
31. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84 (1): 23-7
32. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-8
33. Kallen B. Fluoxetine use in early pregnancy. Birth Defects Res B 2004; 71: 395-6
34. Daniel WA. Mechanisms of cellular distribution of psychotropic drugs: significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 65-73
35. Hansen D, Lou HC, Olsen J. Serious life events and congenital malformations: a national study with complete follow-up. Lancet 2000; 356 (9233): 875-80
36. Carmichael SL, Shaw GM. Maternal life event stress and congenital anomalies. Epidemiology 2000 Jan; 11 (1): 30-5
37. Nimby GT, Lundberg L, Sveger T, et al. Maternal distress and congenital malformations: do mothers of malformed fetuses have more problems? J Psychiatr Res 1999 Jul-Aug; 33 (4): 291-301
38. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29 (5): 918-26
39. Bellantuono C, Migliarese G, Gentile S. Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. Hum Psychopharma-col 2007; 22 (3): 121-8
40. Greene MF. Teratogenicity of SSRIs: serious concern or much ado about little? N Engl J Med 2007 Jun; 356 (26): 2732-3
41. Diav-Citrin O, Shechtman S, Weinbaum D. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort. Teratology 2002; 65 (6): 298
42. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 2006 May; 22 (4): 571-5
43. Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005 Mar; 39 (5): 803-9
44. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156 (11): 1129-32
45. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 Aug; 63 (8): 898-906
46. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 307-8
47. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142 (4): 402-8
48. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48 (10): 996-1000
49. Laine K, Heikkinin T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60 (7): 720-6
50. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65 (2): 230-7
51. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293 (19): 2372-83
52. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006 Feb; 160 (2): 173-6
53. Austin MP. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med 2006 Dec; 36 (12): 1663-70
54. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192: 338-43
55. Isbister GK, Dawson A, Whyte IM, et al. Neonatal parox-etine withdrawal syndromeor actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001 Sep; 85 (2): F147-8
56. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24 (3): 183-97
57. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996 Oct; 16 (5): 356-62
58. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17 (2): 93-101
59. Miksys S, Rao Y, Hoffmann E, et al. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002 Sep; 82 (6): 1376-87
60. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004 Dec; 26 (6): 685-7
61. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23 (5): 587-90
62. Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Molecular Psychiatry 2008 May; 13: 65-73
63. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 Aug; 164 (8): 1206-13
64. Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008 Jan; 115 (2): 283-9
65. Pearson KH, Nonacs RM, Viguera AC, et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007 Aug; 68 (8): 1284-9
66. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160: 993-6
67. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87
68. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17 (8): 801-6
69. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113 (2): 368-75
70. Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002; 51: 443-53
71. Oberlander TF, Grunau RE, Fitzgerald C, et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005; 115: 411-25
72. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995; 17: 165-71
73. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 4: 258-62
74. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluox-etine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159 (11): 1889-95
75. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002 Aug; 72 (2): 184-91
76. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003 Apr; 73 (4): 330-7
77. Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006 Jun; 163 (6): 1026-32
78. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor anti-depressant during pregnancy. Arch Pediatr Adolesc Med 2007 Jan; 161 (1): 22-9
79. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum Dev 2001 Oct; 65 (1): 21-37
80. Buznikov GA, Lambert HW, Lauder JM. Serotonin and serotonin-like substances as regulators of early embryogene-sis and morphogenesis. Cell Tissue Res 2001; 305: 177-86
81. Moiseiwitsch JR, Lauder JM. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci U S A 1995; 92: 7182-6
82. Yavarone MS, Shuey DL, Tamir H, et al. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993; 47: 573-84
83. Shuey DL, Sadler TW, Tamir H, et al. Serotonin and morphogenesis: transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol (Berl) 1993; 187: 75-85
84. Choi DS, Kellermann O, Richard S, et al. Mouse 5-HT2B receptor-mediated serotonin trophic functions. Ann N Y Acad Sci 1998; 861: 67-73
85. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neuroscience 2003; 21: 417-24
86. Davies TS, Kluwe WM. Preclinical toxicological evaluation of sertraline hydrochloride. Drug Chem Toxicol 1998; 21: 521-37
87. Baldwin JA, Davidson EJ, Pritchard AL, et al. The reproductive toxicology of paroxetine. Acta Psychiatr Scand 1989; 80 Suppl. 350: 37-9
88. Byrd RA, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994; 22: 511-8
89. Stewart JD, Rayburn WF, Gonzalez CL, et al. Impact of antenatal paroxetine (Paxil) exposure on perinatal and neonatal outcomes of mice. Neurotoxicol Teratol 1998; 20 (3): 365-6
90. Vorhees CV, Acuff-Smith KD, Schilling MA, et al. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994 Aug; 23 (2): 194-205
91. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25: 59-73
92. Hansson SR, Mezey E, Hoffman BJ. Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 1999; 89 (1): 243-65
93. Singh Y, Jaiswal AK, Singh M, et al. Effect of prenatal diazepam, phenobarbital, haloperidol and fluoxetine exposure on foot shock induced aggression in rats. Indian J Exp Biol 1998 Oct; 36 (10): 1023-4
94. Crowley JM, Dopheide M, Countryman RA, et al. Early developmental exposure to fluoxetine (Prozac): enduring effects on learning, memory, and aggression. Neurotoxicol Teratol 2001; 23 (3): 289
95. Coleman FH, Christensen HD, Gonzalez CL, et al. Behavioral changes in developing mice after prenatal exposure to paroxetine (Paxil). Am J Obstet Gynecol 1999 Nov; 181 (5 Pt 1): 1166-71
96. Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26: 547-62